WO1996019220A1 - A combination product comprising nitazoxanide and an anti-ulcer agent - Google Patents
A combination product comprising nitazoxanide and an anti-ulcer agent Download PDFInfo
- Publication number
- WO1996019220A1 WO1996019220A1 PCT/IE1995/000064 IE9500064W WO9619220A1 WO 1996019220 A1 WO1996019220 A1 WO 1996019220A1 IE 9500064 W IE9500064 W IE 9500064W WO 9619220 A1 WO9619220 A1 WO 9619220A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- combination product
- bismuth
- ulcer agent
- nitazoxanide
- ranitidine
- Prior art date
Links
- 239000003699 antiulcer agent Substances 0.000 title claims abstract description 20
- YQNQNVDNTFHQSW-UHFFFAOYSA-N acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 title claims abstract description 14
- 229960002480 nitazoxanide Drugs 0.000 title claims abstract description 14
- 239000013066 combination product Substances 0.000 title claims description 29
- 229940127555 combination product Drugs 0.000 title claims description 29
- KKMOSYLWYLMHAL-UHFFFAOYSA-N 2-bromo-6-nitroaniline Chemical compound NC1=C(Br)C=CC=C1[N+]([O-])=O KKMOSYLWYLMHAL-UHFFFAOYSA-N 0.000 claims abstract description 8
- ZREIPSZUJIFJNP-UHFFFAOYSA-K bismuth subsalicylate Chemical compound C1=CC=C2O[Bi](O)OC(=O)C2=C1 ZREIPSZUJIFJNP-UHFFFAOYSA-K 0.000 claims abstract description 6
- 229960000782 bismuth subsalicylate Drugs 0.000 claims abstract description 6
- 229960000620 ranitidine Drugs 0.000 claims abstract description 4
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims abstract description 4
- 238000011282 treatment Methods 0.000 claims abstract description 4
- 208000015181 infectious disease Diseases 0.000 claims abstract 3
- 238000011321 prophylaxis Methods 0.000 claims abstract 3
- 150000001622 bismuth compounds Chemical class 0.000 claims description 7
- 229960001520 ranitidine hydrochloride Drugs 0.000 claims description 7
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical group [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 claims description 7
- 229910052797 bismuth Inorganic materials 0.000 claims description 6
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 4
- 229960004645 bismuth subcitrate Drugs 0.000 claims description 3
- REKWPXFKNZERAA-UHFFFAOYSA-K bismuth;2-carboxyphenolate Chemical compound [Bi+3].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O REKWPXFKNZERAA-UHFFFAOYSA-K 0.000 claims description 3
- ZQUAVILLCXTKTF-UHFFFAOYSA-H bismuth;tripotassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[K+].[K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZQUAVILLCXTKTF-UHFFFAOYSA-H 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000003485 histamine H2 receptor antagonist Substances 0.000 claims description 3
- RXPAJWPEYBDXOG-UHFFFAOYSA-N hydron;methyl 4-methoxypyridine-2-carboxylate;chloride Chemical compound Cl.COC(=O)C1=CC(OC)=CC=N1 RXPAJWPEYBDXOG-UHFFFAOYSA-N 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 2
- 229960001380 cimetidine Drugs 0.000 claims description 2
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical group N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims description 2
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960001596 famotidine Drugs 0.000 claims description 2
- 229960004872 nizatidine Drugs 0.000 claims description 2
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 claims description 2
- 229960000381 omeprazole Drugs 0.000 claims description 2
- 239000000612 proton pump inhibitor Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 1
- 150000001621 bismuth Chemical class 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 241000590002 Helicobacter pylori Species 0.000 description 3
- 206010020601 Hyperchlorhydria Diseases 0.000 description 3
- 229940037467 helicobacter pylori Drugs 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- FSAJRXGMUISOIW-UHFFFAOYSA-N bismuth sodium Chemical compound [Na].[Bi] FSAJRXGMUISOIW-UHFFFAOYSA-N 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
Definitions
- Nitazoxanide is the accepted name for 2-(acetolyloxy)-N-(S-Nitro-2- thiazolye benzamide). It is used to treat a broad range of parasitic infections.
- the combined product has the potent activity of an anti- ulcer agent and the anti-parasitic activity associated with nitazoxanide.
- the anti-ulcer agent is a histamine H 2 receptor antagonist.
- the anti- ulcer agent may be selected from cimetidine, ranitidine, famotidine, nizatidine and pharmaceutically acceptable salts thereof. Particularly preferred are ranitidine hydrochloride as Form I or Form II which are potent histamine H 2 - antagonists, and may be introduced for therapeutical use to reduce hyperacidity in the stomach.
- the anti-ulcer agent is a gastric proton pump inhibitor such as omeprazole and pharmaceutically acceptable salts thereof.
- a gastric proton pump inhibitor such as omeprazole and pharmaceutically acceptable salts thereof.
- Helicobacter pylori is associated with histologically related gastritis and hyperchlorhydria. Helicobacter pylori is particularly sensitive to the combination product of the invention.
- the weight ratio of nitazoxanide to anti-ulcer agent, particularly ranitidine hydrochloride is from 2:1 to 5:1, preferably from 3:1 to 4:1, most preferably approximately 10:3.
- the combination product includes bismuth salts which have been used extensively as antacids for the treatment of hyperacidity and dyspepsia.
- the bismuth compound is selected from bismuth citrate, bismuth subcitrate, bismuth salicylate, bismuth subsalicylate, bismuth nitrate, bismuth galate, dibismuth trietraoxidialuminate and hydrate thereof.
- the bismuth compound is bismuth subsalicylate.
- the bismuth compound is bismuth citrate.
- the combination product has improved antibacterial activity against Helicobacter pylori .
- Nitazoxanide may be administered at the same time as the anti-ulcer agent or separately.
- the combination product may be provided in a single formulation, especially for oral administration as a capsule or tablet.
- the pharmaceutical composition may contain suitable excipients and/or vehicles which are conventionally used in galenical pharmacy.
- the combination product may be used in treating gastrointestinal disorders or prophylactically.
- a batch of tablets was prepared by direct compression from the following ingredients:
- the new combinations can be formulated in any suitable galenical forms particularly for oral administration, especially as tablets or capsules.
- the preferable dosage of the present invention is 650mg to 2g, preferably 1.3g per day.
- the combination products described above have the potent anti-ulcer activity of anti-ulcer agents such as ranitidine hydrochloride combined with the antibiotic activity associated with nitazoxanide.
- the product may include bismuth salts such as bismuth subsalicylate, bismuth nitrate, bismuth subcitrate, bismuth galate, bismuth salicylate, dibismuth trietraoxidialuminate and hydrate thereof and especially bismuth citrate.
- bismuth salts such as bismuth subsalicylate, bismuth nitrate, bismuth subcitrate, bismuth galate, bismuth salicylate, dibismuth trietraoxidialuminate and hydrate thereof and especially bismuth citrate.
- the bismuth salts provide a synergistic antibacterial activity.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A combination of nitazoxanide with an anti-ulcer agent, especially ranitidine has a synergistic therapeutic profile in prophylaxis or treatment of H. pylori related infections. The product may also contain, as an antibacterial agent, bismuth salts such as bismuth subsalicylate or bismuth citrate.
Description
A COMBINATION PRODUCT COMPRISING NITAZOXANIDE AND AN ANTI-ULCER AGENT
INTRODUCTION
The invention relates to a novel combination product of nitazoxanide as well as to pharmaceutical compositions containing them and their therapeutic use. Nitazoxanide is the accepted name for 2-(acetolyloxy)-N-(S-Nitro-2- thiazolye benzamide). It is used to treat a broad range of parasitic infections.
STATEMENTS OF INVENTION
It has now been surprisingly found that a combination product of nitazoxanide and an anti-ulcer agent shows a synergistic therapeutical profile.
The combined product has the potent activity of an anti- ulcer agent and the anti-parasitic activity associated with nitazoxanide. In one embodiment of the invention the anti-ulcer agent is a histamine H2 receptor antagonist. In this case the anti- ulcer agent may be selected from cimetidine, ranitidine, famotidine, nizatidine and pharmaceutically acceptable salts thereof. Particularly preferred are ranitidine hydrochloride as Form I or Form II which are potent histamine H2- antagonists, and may be introduced for therapeutical use to reduce hyperacidity in the stomach.
In another embodiment of the invention the anti-ulcer agent is a gastric proton pump inhibitor such as omeprazole and pharmaceutically acceptable salts thereof.
In recent years it has been realised that Helicobacter pylori is associated with histologically related gastritis and hyperchlorhydria. Helicobacter pylori is particularly sensitive to the combination product of the invention. In one embodiment of the invention the weight ratio of nitazoxanide to anti-ulcer agent, particularly ranitidine hydrochloride is from 2:1 to 5:1, preferably from 3:1 to 4:1, most preferably approximately 10:3.
In one embodiment of the invention the combination product includes bismuth salts which have been used extensively as antacids for the treatment of hyperacidity and dyspepsia.
Such bismuth salts are described in British Pharmaceutical
Codex (1949) and include bismuth citrate, bismuth - and ammonium citrate, sodium bismuthyl tartarate, acidic bismuth sodium tartarate, an acidic solution of bismuth a concentrated solution of bismuth; and solutions of bismuth
- and ammonium citrate.
In one embodiment of the invention the bismuth compound is selected from bismuth citrate, bismuth subcitrate, bismuth salicylate, bismuth subsalicylate, bismuth nitrate, bismuth galate, dibismuth trietraoxidialuminate and hydrate thereof.
In a particularly preferred embodiment of the invention the bismuth compound is bismuth subsalicylate. According to another preferred embodiment of the invention the bismuth compound is bismuth citrate.
The combination product has improved antibacterial activity against Helicobacter pylori . Nitazoxanide may be administered at the same time as the anti-ulcer agent or separately. In the case of a concurrent administration
the combination product may be provided in a single formulation, especially for oral administration as a capsule or tablet. The pharmaceutical composition may contain suitable excipients and/or vehicles which are conventionally used in galenical pharmacy.
The combination product may be used in treating gastrointestinal disorders or prophylactically.
DETAILED DESCRIPTION
EXAMPLE 1
A batch of tablets was prepared by direct compression from the following ingredients:
The preferable dosage of the present invention is 650mg to 2g, preferably 1.3g per day. Preferably two separate doses, each of 650mg are administered in a twenty four hour period.
The combination products described above have the potent anti-ulcer activity of anti-ulcer agents such as ranitidine hydrochloride combined with the antibiotic activity associated with nitazoxanide.
The product may include bismuth salts such as bismuth subsalicylate, bismuth nitrate, bismuth subcitrate, bismuth galate, bismuth salicylate, dibismuth trietraoxidialuminate and hydrate thereof and especially bismuth citrate.
Where present, the bismuth salts provide a synergistic antibacterial activity.
Many variations on the specific embodiments of the invention described will be readily apparent and accordingly the invention is not limited to the embodiments described which may be varied in detail.
Claims
1. A combination product comprising nitazoxanide and an anti-ulcer agent.
2. A combination product as claimed in claim 1 wherein the anti-ulcer agent is a histamine H2 receptor antagonist.
3. A combination product as claimed in claim 1 or 2 wherein the anti-ulcer agent is selected from cimetidine, ranitidine, famotidine, nizatidine and pharmaceutically acceptable salts thereof .
4. A combination product as claimed in any of claims
1 to 3 wherein the anti-ulcer agent is ranitidine.
5. A combination product as claimed in any preceding claim wherein the anti-ulcer agent is ranitidine hydrochloride - Form II.
6. A combination product as claimed in any of claims
1 to 4 wherein the anti-ulcer agent is ranitidine hydrochloride - Form I .
7. A combination product as claimed in any preceding claim wherein the weight ratio of nitazoxanide to anti-ulcer agent is from 2:1 to 5:1.
8. A combination product as claimed in claim 7 wherein the weight ratio is from 3:1 to 4:1.
9. A combination product as claimed in claim 7 or 8 wherein the weight ratio is approximately 10:3.
10. A combination product as claimed in claim 1 or any of claims 7 to 9 wherein the anti-ulcer agent is a gastric proton pump inhibitor.
11. A combination product as claimed in claim 1 or any of claims 7 to 10 wherein the anti-ulcer agent is omeprazole and pharmaceutically acceptable salts thereof.
12. A combination product as claimed in any preceding claim including a bismuth compound.
13. A combination product as claimed in claim 12 wherein the bismuth compound is selected from bismuth citrate, bismuth subcitrate, bismuth salicylate, bismuth subsalicylate, bismuth nitrate, bismuth galate, dibismuth trietraoxidialuminate and hydrate thereof.
14. A combination product as claimed in claim 12 or 13 wherein the bismuth compound is bismuth subsalicylate.
15. A combination product as claimed in claim 12 or 13 wherein the bismuth compound is bismuth citrate.
16. A combination product substantially as hereinbefore described with reference to the example.
17. A pharmaceutical composition for oral administration incorporating a combination product as claimed in any preceding claim.
18. A composition as claimed in claim 17 in the form of a tablet.
19. A composition as claimed in claim 17 in the form of a capsule.
20. A pharmaceutical composition for oral administration comprising nitazoxanide and ranitidine hydrochloride.
21. A pharmaceutical composition for oral administration comprising nitazoxanide and ranitidine hydrochloride in a weight ratio of approximately 10:3.
22. A pharmaceutical composition substantially as hereinbefore described with reference to the example.
23. Use of a combination product as claimed in any of claims 1 to 16 for the prophylaxis or treatment of H. pylori related infections.
24. Use of a combination product substantially as hereinbefore described with reference to the example.
25. A method of prophylaxis or treatment of H. pylori related infections comprising administering combination product as claimed in any of claims 1 to 16.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU43992/96A AU4399296A (en) | 1994-12-19 | 1995-12-19 | A combination product comprising nitazoxanide and an anti-ulcer agent |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IE940972 | 1994-12-19 | ||
| IE940972 | 1994-12-19 | ||
| IE950090 | 1995-02-06 | ||
| IE950090A IE950090A1 (en) | 1995-02-06 | 1995-02-06 | Pharmaceutical composition |
| IE950149 | 1995-02-23 | ||
| IE950149 | 1995-02-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1996019220A1 true WO1996019220A1 (en) | 1996-06-27 |
Family
ID=27270487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IE1995/000064 WO1996019220A1 (en) | 1994-12-19 | 1995-12-19 | A combination product comprising nitazoxanide and an anti-ulcer agent |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU4399296A (en) |
| WO (1) | WO1996019220A1 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8895077B2 (en) * | 2007-04-02 | 2014-11-25 | Mount Sinai School Of Medicine | Methods for preventing or treating infectious diseases caused by extracellular microorganisms, including antimicrobial-resistant strains thereof, using gallium compounds |
| WO2018167103A1 (en) * | 2017-03-13 | 2018-09-20 | Genfit | Pharmaceutical compositions for combination therapy |
| WO2020176067A1 (en) * | 2019-02-25 | 2020-09-03 | Rhode Island Hospital | Methods for treating diseases or infections caused by or associated with h. pylori using a halogenated salicylanilide |
| US11285164B2 (en) | 2014-09-12 | 2022-03-29 | UNION therapeutics A/S | Antibacterial use of halogenated salicylanilides |
| US11419834B2 (en) | 2019-02-25 | 2022-08-23 | Rhode Island Hospital | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide |
| US11529361B2 (en) | 2015-05-29 | 2022-12-20 | UNION therapeutics A/S | Halogenated salicylanilides for treating Clostridium infections |
| US12036312B2 (en) | 2016-03-16 | 2024-07-16 | UNION therapeutics A/S | Non-aqueous topical compositions comprising a halogenated salicylanilide |
| US12239635B2 (en) | 2018-06-14 | 2025-03-04 | The Trustees Of Columbia University In The City Of New York | Treatment of cognitive disorders using nitazoxanide (NTZ), nitazoxanide (NTZ) analogs, and metabolites thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0480691A2 (en) * | 1990-10-11 | 1992-04-15 | Merck & Co. Inc. | Combination therapy for peptic ulcer treatment |
| DE4317449A1 (en) * | 1993-05-19 | 1994-11-24 | Asche Ag | Pharmaceutical composition for the treatment of disorders of the gastrointestinal tract |
-
1995
- 1995-12-19 WO PCT/IE1995/000064 patent/WO1996019220A1/en active Application Filing
- 1995-12-19 AU AU43992/96A patent/AU4399296A/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0480691A2 (en) * | 1990-10-11 | 1992-04-15 | Merck & Co. Inc. | Combination therapy for peptic ulcer treatment |
| DE4317449A1 (en) * | 1993-05-19 | 1994-11-24 | Asche Ag | Pharmaceutical composition for the treatment of disorders of the gastrointestinal tract |
Non-Patent Citations (2)
| Title |
|---|
| J.R. MURPHY ET AL.: "Pre-clinical toxicology of nitazoxanide, a new antiparasitic compound.", J.APPL. TOXICOL., vol. 5, no. 2, 1985, pages 49 - 52, XP000569036 * |
| R. CAVIER ET AL.: "Pharmacologic study of various anthelmintic combinations.", REV. MED. VET., vol. 133, no. 12, 1982, pages 779 - 783, XP000569161 * |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8895077B2 (en) * | 2007-04-02 | 2014-11-25 | Mount Sinai School Of Medicine | Methods for preventing or treating infectious diseases caused by extracellular microorganisms, including antimicrobial-resistant strains thereof, using gallium compounds |
| US11285164B2 (en) | 2014-09-12 | 2022-03-29 | UNION therapeutics A/S | Antibacterial use of halogenated salicylanilides |
| US11324761B2 (en) | 2014-09-12 | 2022-05-10 | UNION therapeutics A/S | Antibacterial use of halogenated salicylanilides |
| US11331327B2 (en) | 2014-09-12 | 2022-05-17 | UNION therapeutics A/S | Antibacterial use of halogenated salicylanilides |
| US11529361B2 (en) | 2015-05-29 | 2022-12-20 | UNION therapeutics A/S | Halogenated salicylanilides for treating Clostridium infections |
| US12036312B2 (en) | 2016-03-16 | 2024-07-16 | UNION therapeutics A/S | Non-aqueous topical compositions comprising a halogenated salicylanilide |
| WO2018167103A1 (en) * | 2017-03-13 | 2018-09-20 | Genfit | Pharmaceutical compositions for combination therapy |
| CN110430876A (en) * | 2017-03-13 | 2019-11-08 | 基恩菲特公司 | Pharmaceutical composition for combination treatment |
| US11191749B2 (en) | 2017-03-13 | 2021-12-07 | Genfit | Pharmaceutical compositions for combination therapy |
| IL268751B (en) * | 2017-03-13 | 2022-08-01 | Genfit | Pharmaceutical preparations for combined treatment |
| US12239635B2 (en) | 2018-06-14 | 2025-03-04 | The Trustees Of Columbia University In The City Of New York | Treatment of cognitive disorders using nitazoxanide (NTZ), nitazoxanide (NTZ) analogs, and metabolites thereof |
| WO2020176067A1 (en) * | 2019-02-25 | 2020-09-03 | Rhode Island Hospital | Methods for treating diseases or infections caused by or associated with h. pylori using a halogenated salicylanilide |
| US11419834B2 (en) | 2019-02-25 | 2022-08-23 | Rhode Island Hospital | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide |
Also Published As
| Publication number | Publication date |
|---|---|
| AU4399296A (en) | 1996-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0282132B1 (en) | Compositions and their use for treating gastrointestinal disorders | |
| EP0533281B1 (en) | The use of ranitidine bismuth citrate and in combination with claritromycin or claritromycin and tetracyclin in the manufacture of a medicament for treating gastrointestinal disorders | |
| JPH07502527A (en) | Compositions containing low doses of histamine-H2-receptor antagonists | |
| CA2403994C (en) | Nasal administration of agents for the treatment of gastroparesis | |
| WO1996019220A1 (en) | A combination product comprising nitazoxanide and an anti-ulcer agent | |
| EP0544760B1 (en) | Pharmaceutical compositions containing 5-difluoromethoxy-2- (3,4-dimethoxy-2-pyridyl) methylsulfinyl] benzimidazole and an anti-helicobacter agent for the treatment of gastrointestinal disorders | |
| US6426369B1 (en) | Oxethazaine as antimicrobial agent | |
| IL99471A (en) | Pharmaceutical compositions for treating helicobacter bacteria infections containing 5-fluoromethoxy-2-(3,4-dimethoxy-2-pyridyl)methylsulphinyl)-1h-benzimidazole and salts thereof in combination with an antimicrobial agent | |
| EP0492247A1 (en) | Effervescent H2 blocker formulation | |
| AU758167B2 (en) | Combination preparation for treating malaria | |
| US20100151052A1 (en) | Compositions to alleviate herpes virus symptoms | |
| JPH11508566A (en) | Antibacterial synergistic composition containing rifabutin | |
| IE862599L (en) | Antiinflammatory compositions | |
| EP0715516A1 (en) | Oral compositions of h 2?-antagonists | |
| JPS6213328B2 (en) | ||
| EP0664709A1 (en) | Pharmaceutical composition containing an antimicrobial agent and an antibiotic | |
| IE950954A1 (en) | A combination product. | |
| EP0681476B1 (en) | Unit dose form of bismuth subsalicylate | |
| US6162792A (en) | Use of spiramycin for treating gastrointestinal disorders caused by H. pylori | |
| JP3254712B2 (en) | Pharmaceutical composition | |
| JPS62190126A (en) | Mixed composition of diflunisal and tromethamine | |
| WO1996019232A1 (en) | Combinations of ranitidine hydrochloride-form 1 and bismuth compounds | |
| EP0488041A2 (en) | A pharmaceutical composition for cytomegalovirus infection | |
| AU690664B2 (en) | Low dosage ranitidine compositions for the treatment of minor gastrointestinal disorders associated with excess acid secretion | |
| KR960011773B1 (en) | Pharmaceutical composition for the prevention and treatment of ulcers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DE DK DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase |